Lipum AB (publ) has carried out a directed share issue

Lipum has carried out a directed share issue of approximately SEK 39 million to certain existing and new investors with pronounced long-term interests in the company.

The proceeds will be used primarily to finance the company’s phase I study and for extended pre-clinical studies of the biological drug candidate SOL-116.

Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). Lipum’s shares are listed on Nasdaq First North Growth Market (LIPUM).

Lipum was represented by Mannheimer Swartling in the transaction.